Literature DB >> 3012055

Neurologic complications in oral polio vaccine recipients.

J W Gaebler, M B Kleiman, M L French, G Chastain, C Barrett, C Griffin.   

Abstract

Between April 1982 and June 1983 four children 3 to 24 months of age were referred for evaluation of neurologic abnormalities found to be compatible with vaccine-related poliovirus infection, which had not been suspected by referring physicians. Patients were epidemiologically unrelated residents of Indiana, and none had prior symptoms suggestive of immunodeficiency. All had received poliovirus vaccine orally (first dose in three, fourth dose in one) and a diphtheria-tetanus-pertussis injection in the left anterior thigh within 30 days of symptoms. A vaccine-like strain of poliovirus was isolated from each patient, and each had symptoms (left leg paralysis in three; developmental regression, spasticity, and progressive fatal cerebral atrophy in one) persisting for at least 6 months. Immune function was normal in two with poliovirus type 3 infection, and abnormal (hypogammaglobulinemia, combined immunodeficiency) in two with type 1 and type 2 infection, respectively. The incidence of observed vaccine-related poliovirus infection in Indiana recipients of orally administered poliovirus vaccine was 0.058 per 100,000 per year, significantly greater (P less than 0.001) than predicted.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3012055     DOI: 10.1016/s0022-3476(86)80920-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

1.  Rabbit two.

Authors:  G Dunea
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-01

2.  Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated polio viruses is prolonged.

Authors:  E Savilahti; T Klemola; B Carlsson; L Mellander; M Stenvik; T Hovi
Journal:  J Clin Immunol       Date:  1988-03       Impact factor: 8.317

Review 3.  Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.

Authors:  Jean Guo; Sara Bolivar-Wagers; Nivedita Srinivas; Marisa Holubar; Yvonne Maldonado
Journal:  Vaccine       Date:  2015-01-16       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.